OPPORTUNITIES FOR IMPROVING CARBOHYDRATE AND LIPID METABOLISM IN PATIENTS WITH ARTERIAL HYPERTENSION AND OBESITY BY CORRECTION OF GUT MICROBIOTA DISTURBANCES

Authors

DOI:

https://doi.org/10.21856/j-PEP.2022.3.03

Keywords:

arterial hypertension, abdominal obesity, gut microbiota

Abstract

The aim: to study the possibilities of improving the carbohydrate and lipid metabolism in patients with arterial hypertension (AH) with abdominal obesity (AO) by correcting gut microbiota (GM) disorders.Materials and methods. 34 patients with 2-3 degree AH and with I-II degree AO were examined using generally accepted methods. Determination of the quantitative composition of GM was carried out by the method of polymerase chain reaction using the test system “COLONOFLOR-16 (metabolism)” (“ALFA-LAB”, RF). Statistical data analysis was carried out using Microsoft Excel 17.0. using standard methods.Results. The addition of the probiotic Flora Champ GastroStress Relief (Abbott) which contains Lactobacillus acidophilus, Bifidobacterium animalis subsp. lactis and Lactobacillus casei to standard antihypertensive therapy for 8 weeks leads to positive changes in the quantitative composition of GM: a significant increase in the amount of Lactobacillus spp. and Bifidobacterium spp. These changes in GM are associated with a significant decrease in insulin resistance and in blood levels of atherogenic lipid fractions.Conclusions. The prospects for the use of probiotics for the correction of disorders of carbohydrate and lipid metabolism in patients with arterial hypertension with abdominal obesity are shown.

References

Williams B, Mancia G, Spiering W, et al. Eur Heart J 2018;39: 3021-3104.

Ahmadizar F, Ochoa-Rosales C, Glisic M, et al. Br J Clin Pharmacol 2019;85(5): 993-1002. https://doi.org/10.1111/bcp.13898.

Redon J, Martinez F, Pichler G. The metabolic syndrome in hypertension. In: Manual of Hypertension of the European Society of Hypertension. Third edition. Ed. by G. Mancia, G. Grassi, KP. Tsioufis, et al, CRC Press. 2019: 135-147.

ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021: 1-111. https://doi.org/10.1093/eurheartj/ehab484.

Stange EF. Gut microbiome, metabolic syndrome, and atherosclerosis. In: The ESC Textbook of Cardiovascular Medicine. Third edition. Ed. by: AJ. Camm, TF. Luscher, G. Mauer, PW. Serruys, Oxford Univ press, 2019: 1082-1085.

Fadjejenko GD, Gridnjev OJe. Ukr Terapevt Zhurn 2020;4: 55-62.

Koval' SM, Jushko KO, Snigurs'ka IO. Zaporozh Med Zhurn 2020;22(4): 561-567. https://doi.org/10.14739/2310-1210.2020.4.208409.

Koval' SM, Snigurs'ka IO, Jushko KO. Patologija 2020;17(3/50): 313-318.

Koval' SM, Snigurs'ka IO, Jushko KO. Patologija 2021;18(3): 303-310.

Tenorio-Jiménez C, Martínez-Ramírez MJ, Gil A, et al. Clin Trials Nutr 2020;12(1): 124. https://doi.org/10.3390/nu12010124.

Bonora E. Targher G, Alberiche M, et al. Diabetes Care 2000;23: 57.

Obesity: preventing and managing the global epidemic Report of a WHO Consultation, Geneva, 2000: 252 p.

Expert Panel of Detection, Evalution and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert (Adult treatment Panel III). JAMA 2001;285(19): 2486-2497.

Rocha J, Botelho J, Ksiezarek M, et al. Int J Systematic Evolution Microbiol 2020;7(3): 1522-1527.

O'Callaghan А, van Sinderen D. Front Microbiol 2016;7: 925.

Rittiphairoj T, Pongpirul K, Janchot K, et al. Adv Nutr 2021;12(3): 722-734.

Chiu HF, Fang CY, Shen YC, et al. Probiotics Antimicrob Proteins 2021;13(3): 624-632.

Gadelha CJMU, Bezerra AN. J Vasc Bras 2019;18: e20180124.

Downloads

Published

2022-09-15

How to Cite

Коваль, С., Юшко, К., Снігурська, І., & Мисниченко, О. (2022). OPPORTUNITIES FOR IMPROVING CARBOHYDRATE AND LIPID METABOLISM IN PATIENTS WITH ARTERIAL HYPERTENSION AND OBESITY BY CORRECTION OF GUT MICROBIOTA DISTURBANCES. Problems of Endocrine Pathology, 79(3), 21-26. https://doi.org/10.21856/j-PEP.2022.3.03

Issue

Section

CLINICAL ENDOCRINOLOGY